David A. Siegel Silence Therapeutics PLC Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Two Sigma Advisers, LP holds 42,600 shares of SLN stock, worth $292,662. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,600
Previous 39,600
7.58%
Holding current value
$292,662
Previous $229,000
3.49%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding SLN
# of Institutions
54Shares Held
20.6MCall Options Held
0Put Options Held
0-
Tcg Crossover Management, LLC Palo Alto, CA3.03MShares$20.8 Million1.76% of portfolio
-
Siren, L.L.C. New York, NY2.91MShares$20 Million0.59% of portfolio
-
Redmile Group, LLC San Francisco, CA2.16MShares$14.9 Million1.24% of portfolio
-
Lombard Odier Asset Management (Usa) Corp New York, NY1.84MShares$12.7 Million0.69% of portfolio
-
Morgan Stanley New York, NY1.21MShares$8.3 Million0.0% of portfolio
About Silence Therapeutics plc
- Ticker SLN
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,888,400
- Market Cap $247M
- Description
- Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...